Research programme: autologous fibroblast cell therapy - Fibrocell Science

Drug Profile

Research programme: autologous fibroblast cell therapy - Fibrocell Science

Latest Information Update: 24 Nov 2014

Price : $50

At a glance

  • Originator Fibrocell Science
  • Developer Fibrocell Science; Uniformed Services University of the Health Sciences
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Skin disorders

Most Recent Events

  • 18 Nov 2014 Preclinical trials in Skin disorders (Prevention) in USA (Parenteral)
  • 18 Nov 2014 The US FDA approves IND application for autologous fibroblast cell therapy in Skin disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top